Biocon arm Biocon Biologics India and Mylan launched Semglee (insulin glargine injection) in vial and pre-filled pens to assist management excessive blood sugar in grownup and pediatric sufferers with sort 1 and a couple of diabetes, in the U.S.
Semglee, which obtained ultimate approval from the U.S. Food and Drug Administration (USFDA), has an an identical amino acid sequence to Sanofi’s Lantus and is authorized for a similar indications, as per an organization assertion.
“The availability of Semglee provides another treatment option for patients living with diabetes in the U.S. We rigorously compared Semglee to the reference insulin glargine in participants with type 1 and 2 diabetes and found that Semglee yielded similar (non-inferior) glycemic results in both groups,” mentioned Dr. Thomas Blevins, M.D., lead investigator for the INSTRIDE scientific trials.
“The U.S. launch of Semglee takes us closer to realising our aspiration of reaching one in five insulin-dependent people with diabetes worldwide,” mentioned Kiran Mazumdar-Shaw, govt chairperson, Biocon.
The firm has been increasing reasonably priced entry to biosimilar insulins to sufferers in Japan, Australia, Europe, India and different rising markets. In the U.S. They will supply Semglee at a wholesale value of $147.98 per package deal of 5 3ml pens and $98.65 per 10ml vial, representing the bottom WAC (wholesale acquisition price) for any long-acting insulin glargine after a list-price low cost of 65%, as per an announcement.